Status:
COMPLETED
Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors
Lead Sponsor:
Vanderbilt University Medical Center
Collaborating Sponsors:
National Center for Research Resources (NCRR)
American Cancer Society, Inc.
Conditions:
Arthralgia
Breast Cancer
Eligibility:
FEMALE
35-90 years
Brief Summary
RATIONALE: Gathering information over time about joint pain and stiffness from postmenopausal women with early-stage breast cancer who are receiving aromatase inhibitors may help doctors plan treatmen...
Detailed Description
OBJECTIVES: Primary * Estimate the incidence, time to onset, prevalence, and clinical and demographic predictors of arthralgia in post-menopausal women with early-stage breast cancer receiving aroma...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Planning to begin aromatase inhibitor (AI) therapy or taken fewer than 10 doses of adjuvant AI therapy
- Hormone-receptor status not specified
- PATIENT CHARACTERISTICS:
- Postmenopausal
- ECOG performance status 0-1
- Able to understand and respond to questions in English
- No condition that would impair the ability to provide informed consent
- No other non-breast cancer condition
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No more than 9 prior doses of AI
Exclusion
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
351 Patients enrolled
Trial Details
Trial ID
NCT00954564
Start Date
June 1 2009
End Date
May 1 2014
Last Update
April 4 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37203
2
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838